Abstracts Archive - Page 171 of 2607 - ACR Meeting Abstracts

Abstract Number: 1000 • ACR Convergence 2025
A Deep-Learning Based Approach Uncovers Novel Mediators of Micro-RNA Restraint of Type-2 Immunity
Shaan Sekhon¹, Robin Kageyama², Neil Sprenkle³, Hannah Happ², Eric Wigton², Heather Pua³ and Mark Ansel², ¹University of California, San Francisco, Berkeley, ²University of California, San Francisco, San Francisco, ³Vanderbilt University, Nashville
Background/Purpose: MicroRNAs, such as miR-24 and miR-27, co-expressed within the Mirc11 and Mirc22 clusters, orchestrate a regulatory network critical to Th2 cell differentiation and cytokine…
Abstract Number: 0056 • ACR Convergence 2025
Repository Corticotropin Injection Reduces Inflammation and Bone Turnover Markers in the Murine CIA Model
Maripat Corr¹, Grace Hsueh², Aaron place², David Lucas² and NANCY LANE³, ¹ucsd, San Diego, CA, ²ANI Pharmaceuticals, Inc., Baudette, MN, ³University of California at Davis, School of Medicine, Sacramento, CA
Background/Purpose: Melanocortin receptor agonists, such as adrenocorticotropic hormone (ACTH), are anti-inflammatory with pleotropic functions. We aimed to evaluate the effects of a repository corticotropin injection…
Abstract Number: 0511 • ACR Convergence 2025
Submandibular Gland Ratio Stratifies Salivary Function and Reveals a Senescence Peak in Anti-SSA Positive Sjögren’s Syndrome
Chiao-Feng Cheng¹, Tseng-Cheng Chen², Min-Shu Hsieh³, TING-YUAN LAN⁴, Jui-Hung Kao⁵, Yu Heng Lin⁶, Mei-Fang Cheng⁷, Yi-Chieh Chen⁸, Hsiao-Sang Chu⁹, Yi-Min Huang¹⁰, Cheng-Hsun Lu¹¹, Ko-Jen Li¹¹, Chieh-Yu Shen¹ and Song-Chou Hsieh¹², ¹Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ²Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ³Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei ¹⁰⁰²²⁵, Taiwan, Taipei, Taiwan (Republic of China), ⁴National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ⁵Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Taipei, Taiwan (Republic of China), ⁶Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan, Taipei, Taiwan (Republic of China), ⁷Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ⁸Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan., Taipei, Taiwan (Republic of China), ⁹Department of Ophthalmology, National Taiwan University Hospital, Taipei City, Taiwan., Taipei, Taiwan (Republic of China), ¹⁰Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ¹¹National Taiwan University Hospital, Taipei, Taiwan, ¹²National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: In primary Sjögren’s syndrome (pSS), the histologic focus score reflects immune infiltration but does not capture irreversible glandular damage. We evaluated a submandibular gland…
Abstract Number: 0495 • ACR Convergence 2025
Effectiveness and Safety of Iguratimod with Background Methotrexate Therapy in Indian Patients with Rheumatoid Arthritis: A Randomized Double Blinded Placebo Controlled Study
MIDHUN SAKRAVARTHY JALANATHAN¹, Mehdi Ali Mirza¹, Vijaya prasanna Parimi², Seethalakshmi S¹ and Tejaswini Ramineni³, ¹ESIC Medical College and Hospital, Sanathanagar, Hyderabad, Telangana, India, ²ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India, ³Esic Medical College And Hospital, Sanathnagar, Hyderabad, Telangana, India
Background/Purpose: Iguratimod (IGU), an oral synthetic disease-modifying antirheumatic drug (DMARD), has shown significant efficacy and safety in rheumatoid arthritis (RA) when combined with methotrexate (MTX)…
Abstract Number: 0663 • ACR Convergence 2025
iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
Parastoo Fazeli¹, Jennifer Medlin², Andrew BitMansour³, Debra Zack⁴, Rebecca Elstrom⁵, Bertha Villa⁵, Lilly Wong⁶, John Goulding⁷, Nicholas Brookhouser⁵, Trever Greene⁵, Cara Bickers⁵, Carol Wong⁵, Beatrice Ferguson⁵, Tom Lee⁵, Jode Goodridge⁵, Marie Hu⁸, Veronika Bachanova⁸, Jeffrey Miller⁹, Bahram Valamehr⁶, Matthew Lunning¹⁰ and Vaneet Sandhu⁵, ¹UMN, ST PAUL, MN, ²University of Nebraska Medical Center, Omaha, NE, ³Fate Therapeutics, Inc., San Carlos, CA, ⁴Fate Therapeutics, Inc., Solana Beach, CA, ⁵Fate Therapeutics, Inc., San Diego, ⁶Fate Therapeutics, Inc., San Diego, CA, ⁷Fate Therapeutics, San Diego, ⁸University of Minnesota, Minneapolis, ⁹University of Minnesota, Minneaspolis, MN, ¹⁰University of Nebraska, Omaha
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy shows promise in autoimmune disease. However, autologous CAR T-cell therapy is limited by prolonged pre- and…
Abstract Number: 0752 • ACR Convergence 2025
Characterization of patients with polymyalgia rheumatica in the ARTESER giant cell arteritis cohort
Maite Silva-Diaz¹, Marta Domínguez-Álvaro², Rafael B. Melero-González³, Elisa Fernández-Fernández⁴, Jesús Alejandro Valero⁵, Ismael González⁶, Julio Sánchez Martín⁷, Javier Narváez⁸, Eva Galíndez Agirregoikoa⁹, Vicente Aldasoro Cáceres¹⁰, lydia Abasolo Alcazar¹¹, Javier Loricera¹², Noemí Garrido¹³, Santos Castañeda¹⁴, Carlota L Iñiguez¹⁵, Alicia Garcia¹⁶, Clara Molina Almela¹⁷, María Alcalde Villar¹⁸, Antonio Juan Mas¹⁹ and Ricardo Blanco²⁰, ¹Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Hospital Universitario Donosti, Donosti, Spain, ⁶Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ⁷Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁸Hospital Universitario de Bellvitge, Barcelona, Spain, ⁹BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁰Hospital Universitario de Navarra, Pamplona, Spain, ¹¹IdISSC. HCSC, Madrid, Madrid, Spain, ¹²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹³Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ¹⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁵Hospital del Bierzo, Ponferrada, Castilla y Leon, Spain, ¹⁶Rheumatologist, La Laguna, Spain, ¹⁷Consorci Hospital General Universitari de València, Valencia, Spain, ¹⁸Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, Madrid, Spain, ¹⁹Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain, ²⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Giant cell arteritis (GCA) is a chronic granulomatous vasculitis affecting medium- and large-sized arteries (1). The classic symptoms are cranial symptoms, including headache, jaw…
Abstract Number: 1084 • ACR Convergence 2025
Access to rheumatology care in patients with new diagnosis of polymyalgia rheumatica: analysis from a national inception cohort
Sebastian E Sattui¹, Orysya Soroka², Manuel Carpio Tumba³, Emily Holladay⁴, Fenglong Xie⁵, Sarah Mackie⁶, Jeffrey Curtis⁷, Robyn Domsic³ and Iris Navarro-Millan⁸, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Weill Cornell Medicine, New York, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Alabama at Birmingham, Edmond, OK, ⁵The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Leeds, Leeds, United Kingdom, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY
Background/Purpose: Patients with polymyalgia rheumatica (PMR) are commonly diagnosed and cared for by non-rheumatology providers (i.e., primary care). Lack of access to specialty care can…
Abstract Number: 1004 • ACR Convergence 2025
Single-Cell Analysis Reveals Tissue Resident Memory T Cells Heterogeneity in the Joint
Yang Yang¹, Yusuke Miyashita², Madison Mangin³, Kellen Winden¹, Peter Nigrovic² and Margaret Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Brookline, MA, ³Boston Children's Hospital, St Simons Island, GA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint-specific memory, the phenomenon in which arthritis repeatedly flares in the same joints. We…
Abstract Number: 1015 • ACR Convergence 2025
Refining Administrative Algorithms For Accurate Identification of Patients with Systemic Sclerosis In Trinetx Research Network
Gulsen Ozen¹, Michael O'Rorke², Paul Romitti² and Robyn Domsic³, ¹University of Iowa, Carver College of Medicine, Division of Immunology, Coralville, IA, ²University of Iowa College of Public Health, Department of Epidemiology, Iowa City, IA, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Large data-driven medical research is invaluable in answering questions about epidemiology, genetics, therapeutics, and outcomes of rare diseases. Systemic sclerosis (SSc) is rare yet…
Abstract Number: 1091 • ACR Convergence 2025
Safety Profile of ICIs in Patients with Rheumatoid Arthritis: Results from a Propensity Score-Matched Cohort Study
Betul Ibis¹, Furkan Bahar¹, Yu-Che Lee², Ko-Yun Chang³, Yu Chang⁴ and Cho-Han Chiang⁵, ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²University at Buffalo, Buffalo, NY, ³National Jewish Health, Denver, CO, ⁴National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ⁵Mount Auburn Hospital, Harvard Medical School, Cambridge
Background/Purpose: Immune-related adverse events (irAEs) are a significant concern for patients receiving immune checkpoint inhibitors (ICIs), particularly those with pre-existing rheumatoid arthritis (RA). Managing ICIs…
Abstract Number: 1107 • ACR Convergence 2025
Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium
Laura Cappelli¹, Namrata Singh², Noha Abdel-Wahab³, Anne R. Bass⁴, Tawnie Braaten⁵, Cassandra Calabrese⁶, Nilasha Ghosh⁷, Tamiko Katsumoto⁸, Sang Kim⁹, Minna Kohler¹⁰, Alexa Meara¹¹, Pankti Reid¹², Jeffrey Sparks¹³, Maria Suarez-Almazor¹⁴, Clifton Bingham¹⁵ and Ami Shah¹⁶, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²University of Washington, Bellevue, WA, ³University of Texas MD Anderson Cancer Center, houston, TX, ⁴Hospital for Special Surgery, New York, NY, ⁵UNIVERSITY OF UTAH, Salt Lake City, UT, ⁶Cleveland Clinic Foundation, Cleveland Heights, OH, ⁷Hospital for Special Surgery, New York, NY, ⁸Division of Immunology and Rheumatology, Stanford University, Millbrae, CA, ⁹Yale University, Branford, CT, ¹⁰Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹¹The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹²University of Chicago Medical Center, Chicago, IL, ¹³Brigham and Women's Hospital, Boston, MA, ¹⁴MD Anderson Cancer Center, Houston, TX, ¹⁵Johns Hopkins University, Baltimore, MD, ¹⁶Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: Large, multi-center efforts are needed to optimally study rheumatic immune-related adverse events (rh-irAEs) from immune checkpoint inhibitor (ICI) use. We aimed to characterize the…
Abstract Number: 1068 • ACR Convergence 2025
Association Between Social Determinants of Health Domains and COVID-19-Related Hospitalization in Individuals with Autoimmune Rheumatic Diseases: A Retrospective Analysis of National U.S. Data
Londyn Robinson¹, jerrod anzalone², Jasvinder Singh³, Kaleb Michaud², Lesley Jackson⁴, Maria I. ("Maio") Danila⁵, Dongmei Li⁶, Rena Patel⁴ and Namrata Singh⁷, ¹University of Washington, Seattle, WA, ²University of Nebraska Medical Center, Omaha, NE, ³Baylor College of Medicine, Houston, TX, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ⁶University of Rochester School of Medicine and Dentistry, Rochester, NY, ⁷University of Washington, Bellevue, WA
Background/Purpose: Although studies have been published on the baseline characteristics of patients with autoimmune rheumatic diseases (AIRDs) with COVID-19 infection, little data exists on how…
Abstract Number: 1095 • ACR Convergence 2025
Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series
dellal azeddine¹, Jean-Guillaume Letarouilly², Jacques Morel³, René-Marc Flipo⁴, Valerie Devauchelle⁵, richette pascal⁶, Philippe Dieude⁷, Hubert Marotte⁸, FELTEN Renaud⁹, LATOURTE Augustin¹⁰, CHEVET Baptiste¹¹, HILLIQUIN Pascal¹², SORDET Christelle⁹, DERNIS mmanuelle¹³, WENDLING Daniel¹⁴, Arsène Mekinian¹⁵, Nathalie BALLANDRAUD¹⁶, Christophe Richez¹⁷, TOURNADRE Anne¹⁸, salmon Jean -Hugues¹⁹, SAILLOT Carine²⁰, kedra joanna²¹, nahon stephane²², LE GOFF Benoit²³, Bruno Fautrel²⁴, Francis BERENBAUM²⁵, David SAADOUN²⁶, PHAM Thao¹⁶ and SELLAM JEREMIE²⁷, ¹GHI LE RAINCY MONTFERMEIL, Montfermeil, France, ²Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, LILLE, Nord-Pas-de-Calais, France, ³CHU and University of Montpellier, Montpellier, France, ⁴Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁵UBO, Brest, France, ⁶Rheumatology Department, Lariboisiere Hospital, Paris, Ile-de-France, France, ⁷Service de Rhumatologie, Hôpital Bichat APHP, Paris, Paris, Ile-de-France, France, ⁸INSERM ¹⁰⁵⁹/University of Saint-Etienne, Saint-Etienne, France, ⁹Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ¹⁰Rheumatology Department, Lariboisiere Hospital, Paris, France, ¹¹CHU BREST, brest, Bretagne, France, ¹²CH SUD FRANCILIEN, PARIS, France, ¹³chu caen, CAEN, Haute-Normandie, France, ¹⁴CHU de Besançon, Besançon, Franche-Comte, France, ¹⁵Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁶CHU MARSEILLE, marseille, Provence-Alpes-Cote d'Azur, France, ¹⁷Bordeaux University Hospital, Bordeaux, France, ¹⁸CHU CLERMONT, CLERMONT, Lorraine, France, ¹⁹CHU REIMS, REIMS, Champagne-Ardenne, France, ²⁰CHU ORLEANS, ORLEANS, Pays de la Loire, France, ²¹Pitié-Salpêtrière Hospital, Rheumatology Department, APHP, Sorbonne University,, Paris, France, ²²GHI LE RAINCY MONTFERMEIL, Montfermeil, Ile-de-France, France, ²³CHU Nantes, Nantes, France, ²⁴Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ²⁵Sorbonne University/Inserm/AP-HP/⁴Moving Biotech, Paris, France, ²⁶CHU LA PITIE SALPETRIERE, PARIS, Ile-de-France, France, ²⁷Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France., Paris, France
Background/Purpose: The use of TNFα antagonist is not recommended if the patient have a suspicion or demyelinating diseases (DD) confirmed [1]. There are a few…
Abstract Number: 1097 • ACR Convergence 2025
Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic review and meta-analysis highlighting differences with the idiopathic forms
Elvis Hysa¹, Andrea Casabella², Emanuele Gotelli³, Rosanna Campitiello⁴, Carlo Genova⁴, Enrica Teresa Tanda⁴, Carmen Pizzorni⁵, Alberto Sulli⁵, Vanessa Smith⁶, Marco Amedeo Cimmino⁷, Sabrina Paolino⁵ and Maurizio Cutolo⁴, ¹University of Genoa, Genoa, Italy, ²IRCCS Ospedale Policlinico San Martino, Genova, Italy, ³University of Genoa, Genoa, Liguria, Italy, ⁴University of Genova, Genova, Italy, ⁵University of Genoa, Genova, Italy, ⁶Ghent University Hospital, Gent, Belgium, ⁷Rheumatology Outpatient Clinic, Villa Ravenna, Chiavari, Italy, Genova, Italy
Background/Purpose: An altered immune tolerance disturbed by immune checkpoint inhibitors (ICIs) may contribute to new-onset polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in treated…
Abstract Number: 1085 • ACR Convergence 2025
Bridging the Gap: The Use of Patient Joint Self-Assessment in RA Treatment Response Evaluation
Sri Lakshmi Sathiyaseelan¹, Sandeep Kansurkar², Kavita Krishna³ and Varsha Bhatt⁴, ¹Bharati Vidyapeeth medical college and hospital, chennai, Tamil Nadu, India, ²Bharti vidyapeeth (DTU) Medical College, Pune, Pune, Maharashtra, India, ³Bharati Vidyapeeth University Medical College and Hospital, Pune, Maharashtra, India, ⁴Department of Clinical Immunology and Rheumatology, Bharati Vidyapeeth (Deemed To Be) University Medical College,Pune, Pune, Maharashtra, India
Background/Purpose: Rheumatoid arthritis presents with multiple joint pains and it is traditionally, examined by the clinicians. The utility of patient self‐joint counts has become an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].